Bosch Health Campus Logo Bosch Health Campus Logo
Home

About

How to find the right drug and the most efficient dosage for a patient? In personalized medicine genetic information of so called pharmacogenes can help to predict whether a medication will produce desired responses or not. Experts of the group „Clinical PGx & Digital Health“ have implemented a pharmacogenomics testing routine at Robert Bosch Hospital that helps physicians to determine the best medication for their patients. Recognizing that drug response arises from complex interactions between genetic and non-genetic factors (e.g. disease-specific pathophysiology, comedications, and lifestyle-related influences), the group systematically investigates these determinants using innovative in vitro and in vivo model systems, complemented by pharmacometric analyses. Together, the findings aim to strengthen the evidence for PGx implementation, refine clinical guidelines, and identify novel and robust predictive biomarkers.

Heads

Prof. Dr. Matthias Schwab
Head of the Institute; Research Group Leader Pharmacogenomics and Digital Health, and of Metabolism and Cancer Therapy
Tel+49-711-8101 3700
matthias.schwab@ikp-stuttgart.de
Go to profile
Dr. Roman Tremmel
Research Group Leader Clinical Pharmacogenomics and Digital Health
Tel+49-711-8101 2061
roman.tremmel@ikp-stuttgart.de
Go to profile

Team Members

Prof. Dr. Anne Nies
Senior Scientist
Tel+49-711-8101 2775
anne.nies@ikp-stuttgart.de
Go to profile
Dr. Kathrin Klein
Senior Scientist
Tel+49-711-8101 5648
kathrin.klein@ikp-stuttgart.de
Go to profile
Dr. Charlotte Kölz
Scientist
Tel+49-711-8101 2741
charlotte.koelz@ikp-stuttgart.de
Go to profile
Dr. Simeon Rüdesheim, Pharmacist
Scientist
Tel+49-681-302 2284
simeon.ruedesheim@uni-saarland.de
Go to profile
Julia Dressler
PhD Student
Tel+49-711-8101 5004
julia.dressler@ikp-stuttgart.de
Jasmin Happle
Study Nurse
Tel+49-711-8101 5969
Jasmin.Happle@ikp-stuttgart.de
Thomas Hees
Technical Assistant
Tel+49-711-8101 2089
thomas.hees@ikp-stuttgart.de
Silvia Hübner
Technical Assistant
Tel+49-711-8101 2094
silvia.huebner@ikp-stuttgart.de

Selected publications of the Research Group

  • Boige V, Menoret E, Le Teuff G, Boyer J-C, Cozic N, Desvignes J-P, Taieb J, Laurent-Puig P, Wettergren Y, Schwab M, Ackland S, Jennings B, Sudaka A, Seutin E, Beroud C, Koudou Y, Etienne-Grimaldi M-C. A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer. J Natl Cancer Inst. 4(118):699–710, 2026. doi: 10.1093/jnci/djaf357.
  • Fragoulakis V, Swen JJ, Koufaki M-I, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung K-C, Deneer VHM, Dupui M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Manson LEN, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, van der Wouden CH, Dávila-Fajardo CL, Dolžan V, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar H-J, Patrinos GP, Mitropoulou C. Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study. EClinicalMedicine(91):103686, 2026. doi: 10.1016/j.eclinm.2025.103686.
  • Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui C-H, Stein CM, Klein TE, Spahn C, Kwon S, Hartono JL, Boer NK de, Ahmad T, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. Clin Pharmacol Ther. 4(119):916–927, 2026. doi: 10.1002/cpt.70209.
  • Tremmel R, Schreeck F, Jaeger S, Schricker S, Schaeffeler E, Igel S, Steinberger D, Pagitz M, Latus J, Ketteler M, Bühl K, Dahlke M-H, Kopp H-G, Schwab M. Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up. Clin Pharmacol Ther. 1(119):241–254, 2026. doi: 10.1002/cpt.70083.
  • Mürdter TE, Schroth W, Goetz MP, Tremmel R, Igel S, Schaeffeler E, Jäger S, Loibl S, Gerteis A, Pfaff L, Bechtner C, Wrobel D, Bernhöft I, Fischer I, Meisner C, Block M, Brauch H, Schwab M. Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial. Clin Cancer Res. 23(31):4903–4911, 2025. doi: 10.1158/1078-0432.CCR-25-2103.
  • Pan L, Tang B, Zhang X, Parini P, Tremmel R, Loscalzo J, Lauschke VM, Maron BA, Paci P, Ernberg I, Tan NS, Végvári Á, Liao Z, Rengarajan S, Zubarev R, Fan Y, Zheng X, Jian X, Sheng R, Wang Z, Li X. Comprehensive analysis of multi-omics single-cell data using the single-cell analyst. Imeta. 3(4):e70038, 2025. doi: 10.1002/imt2.70038.
  • Tremmel R, Hübschmann D, Schaeffeler E, Pirmann S, Fröhling S, Schwab M. Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes. Pharmacol Rev. 1(77):100014, 2025. doi: 10.1124/pharmrev.124.001049.
  • Tremmel R, Zhou Y, Camara MD, Laarif S, Eliasson E, Lauschke VM. PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes. Nucleic Acids Res. D1(53):D1498-D1509, 2025. doi: 10.1093/nar/gkae1016.
  • Buniatian GH, Schwinghammer U, Tremmel R, Cynis H, Weiss TS, Weiskirchen R, Lauschke VM, Youhanna S, Ramos I, Valcarcel M, Seferyan T, Rahfeld J-U, Rieckmann V, Klein K, Buadze M, Weber V, Kolak V, Gebhardt R, Friedman SL, Müller UC, Schwab M, Danielyan L. Consequences of Amyloid-β Deficiency for the Liver. Adv Sci (Weinh). 18(11):e2307734, 2024. doi: 10.1002/advs.202307734.
  • Zwirner S, Abu Rmilah AA, Klotz S, Pfaffenroth B, Kloevekorn P, Moschopoulou AA, Schuette S, Haag M, Selig R, Li K, Zhou W, Nelson E, Poso A, Chen H, Amiot B, Jia Y, Minshew A, Michalak G, Cui W, Rist E, Longerich T, Jung B, Felgendreff P, Trompak O, Premsrirut PK, Gries K, Muerdter TE, Heinkele G, Wuestefeld T, Shapiro D, Weissbach M, Koenigsrainer A, Sipos B, Ab E, Zacarias MO, Theisgen S, Gruenheit N, Biskup S, Schwab M, Albrecht W, Laufer S, Nyberg S, Zender L. First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure. Cell. 7(187):1666-1684.e26, 2024. doi: 10.1016/j.cell.2024.02.023.
  • Nies AT, König J, Leuthold P, Damme K, Winter S, Haag M, Masuda S, Kruck S, Daniel H, Spanier B, Fromm MF, Bedke J, Inui K-I, Schwab M, Schaeffeler E. Novel drug transporter substrates identification: An innovative approach based on metabolomic profiling, in silico ligand screening and biological validation. Pharmacol Res(196):106941, 2023. doi: 10.1016/j.phrs.2023.106941.
  • Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung K-C, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar H-J. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 10374(401):347–356, 2023. doi: 10.1016/S0140-6736(22)01841-4.